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Background: Hodgkin disease (HD) and medulloblastoma (MB) are common malignancies found in children and
young adults, and radiotherapy is part of the standard treatment. It was reported that these patients who received
radiation therapy have an increased risk of cardiovascular late effects. We compared the predicted risk of
developing radiogenic cardiac toxicity after photon versus proton radiotherapies for a pediatric patient with HD
and a pediatric patient with MB.
Methods: In the treatment plans, each patient’s heart was contoured in fine detail, including substructures of the
pericardium and myocardium. Risk calculations took into account both therapeutic and stray radiation doses. We
calculated the relative risk (RR) of cardiac toxicity using a linear risk model and the normal tissue complication
probability (NTCP) values using relative seriality and Lyman models. Uncertainty analyses were also performed.
Results: The RR values of cardiac toxicity for the HD patient were 7.27 (proton) and 8.37 (photon), respectively; the
RR values for the MB patient were 1.28 (proton) and 8.39 (photon), respectively. The predicted NTCP values for the HD
patient were 2.17% (proton) and 2.67% (photon) for the myocardium, and were 2.11% (proton) and 1.92% (photon) for
the whole heart. The predicted ratios of NTCP values (proton/photon) for the MB patient were much less than unity.
Uncertainty analyses revealed that the predicted ratio of risk between proton and photon therapies was sensitive to
uncertainties in the NTCP model parameters and the mean radiation weighting factor for neutrons, but was not sensitive
to heart structure contours. The qualitative findings of the study were not sensitive to uncertainties in these factors.
Conclusions: We conclude that proton and photon radiotherapies confer similar predicted risks of cardiac toxicity for
the HD patient in this study, and that proton therapy reduced the predicted risk for the MB patient in this study.
Keywords: Cardiac toxicity, Hodgkin disease, Medulloblastoma, Mediastinal irradiation, Craniospinal irradiation,
Proton therapy, Normal tissue complication probabilityBackground
Hodgkin disease (HD) and medulloblastoma (MB) are
among the most common malignancies found in children
and young adults, and radiotherapy (mediastinal radiation
for HD and radiotherapy to the cranium and spine for
MB) is part of the standard treatment. Coronary vascular
disease was found to be associated with a higher* Correspondence: rzhang@marybird.com
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reproduction in any medium, provided the orradiation dose in HD survivors [1], and the leading
cause of noncancer mortality in radiation-treated HD
patients is cardiovascular disease [2,3]. It was found that
craniospinal irradiation (CSI) patients are at risk for signifi-
cant cardiac dysfunction and asymmetric impairment of
heart development, where asymmetric distribution of radi-
ation may be the cause [4]. Pediatric survivors who received
radiotherapy and chemotherapy for brain tumors are at
increased risk for cardiovascular late effects [5].
Proton therapy typically delivers a lower dose to normal
tissues than photon therapy [6]. However, stray radiation
dose from neutrons generated during proton therapy is ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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within a patient are computationally complex and have
only recently been accomplished for proton therapy
[8-10]. Recently, there has been much progress in research
to compare the risks of second cancers after photon and
proton radiotherapies [8,10-13]. In contrast, relatively little
attention has been paid in the literature to predictive
comparisons of other late effects, such as cardiac toxicity
[11], for pediatric patients who received radiotherapy.
The aim of this work was to compare the predicted risks
of cardiac toxicity after photon versus proton radiotherapies
for a pediatric HD patient and a pediatric MB patient. Both
therapeutic and secondary radiation doses were included in
the risk predictions. We calculated the therapeutic photon
and proton absorbed doses and secondary photon absorbed
doses using a commercial treatment planning system
(TPS); the secondary radiation dose for proton therapy was
obtained from Monte Carlo simulations. Dose-risk models
from the literature were used to estimate the risk of cardiac
toxicity, and rigorous uncertainty analyses were carried out
on risk predictions.
Methods
Study patients and treatment techniques
For the purposes of this study, we created new proton
and photon treatment plans using the same commercial
TPS (Eclipse version 8.9, Varian Medical Systems, Palo
Alto, CA) for two patients who were formerly treated at
The University of Texas MD Anderson Cancer Center
following protocol approved by our institutional review
board. Both patients were treated with passively scattered
proton therapy with treatment plans having the same
beam arrangements as those planned for this study, but
were originally planned using an earlier version of the TPS
software. Our proton therapy facility uses a synchrotron
accelerator and passive scattered proton beams (PSPT)
were used for the treatment plans in this study. The photon
treatment plans in this study were planned for 6MV beams
delivered using a linear accelerator (Varian 2100, Palo
Alto, CA) equipped with a 120 leaf multileaf collimator
(Millenium, Varian, Palo Alto) [14,15]. We decided not con-
sider intensity modulated proton therapy (IMPT) because
at the time the study was conducted, IMPT was not in
clinical use for HD or MB. Therefore, this would have
reduced the clinical relevance of the paper. Furthermore,
the management of organ motion and interplay effects with
scanned beams are not well understood or sufficiently
developed to allow a comparison of comparable levels of
radiotherapy technologies. Furthermore, IMPT is not even
available at many proton centers.
The first patient was a 10-year-old girl diagnosed with
HD. The clinical target volume (CTV) was delineated by
the radiation oncologist and included demonstrated tumor
and tissue with presumed tumor [16]. The proton treatmentplan comprised parallel opposed anterior-posterior (AP)
and posterior-anterior (PA) fields having energies of 140
and 180 MeV, respectively. A range compensator and colli-
mating aperture for each field were separately designed to
achieve coverage of the CTV while including allowances for
uncertainties in beam range, penumbra, patient set-up, and
potential target motion. The photon plan included five co-
planar intensity-modulated beams with five gantry angles
(0°, 20°, 170°, 190°, and 340°), selected to minimize dose in
the lungs. The CTV was expanded 5 mm isotropically to
create a planning target volume (PTV) for the photon plan,
and the plan was optimized using the inverse planning
method. The total prescribed dose (according to National
Cancer Center Network (NCCN) guideline) was 36
Gy relative biological effectiveness (RBE) (i.e., 32.7
Gy × 1.1 to reflect the biological effectiveness of protons
relative to photons) and 36 Gy for the proton and photon
treatment plans, respectively; 18 fractions were used for
both treatment plans.
The second patient was a 4-year-old boy who was
diagnosed with MB. His proton treatment plan included
right and left posterior oblique cranial fields (gantry
angles 105° and 255°) and two PA spinal fields. The target
volume included the cranial and spinal cavities and entire
vertebral body (to prevent asymmetric bone growth caused
by non-uniform dose distribution in the vertebral bodies).
The photon treatment plan consisted of two opposed
lateral cranial fields (gantry angles 90° and 270°) and one
PA spinal field. The beam energy for all photon fields was
6 MV, and the plan included junction shifts after 9
Gy and 16.2 Gy. The prescribed dose was 23.4 Gy
(RBE) and 23.4 Gy for the proton and photon treatment
plans, respectively; 13 fractions were used for both
treatment plans. Additional details of the CSI treatment
planning can be found elsewhere [14,15].
The external surface of the heart was contoured in
every computed tomography (CT) slice from the inferior
border of the right pulmonary artery to the apex of the
heart. The pericardium was defined as a 2-mm shell
inside the external heart surface contours. The myocardium
was a shell having an external contour identical to the
internal contour of the pericardium and a thickness varying
from 1 cm to 2 cm, with the thickness on the left side being
twice that on the right side.
Dose reconstruction and risk calculation
The therapeutic doses from photon and proton plans
were estimated from the TPS directly. The secondary
dose from proton therapy was calculated by our Monte
Carlo Proton Radiotherapy Treatment Planning system,
which uses the Monte Carlo N-particle eXtended code
(MCNPX, version 2.6, Los Alamos National Laboratory)
[17] as a dose engine. Details of this system were previ-
ously described [8]. The secondary dose from the photon
Table 1 Predicted NTCP and RNTCP values for cardiac structures based on existing model parameters; for the HD
patient, NTCP and RNTCP values based on correct literature parameters were listed; for the MB patient, calculations
were carried out by using all possible parameter sets, and only RNTCP values were listed
HD patient MB patient
Structure Ref. D50 (Gy) n m γ s NTCPProton (%) NTCPPhoton (%) RNTCP RNTCP
Pericardium [26] 48 0.35 0.1 - - - - - 0
Pericardium [25] 50.6 0.64 0.13 - - - - - 1.43 × 10-5
Myocardium [24] 52.2 - - 1.25 0.87 - - - 1.93 × 10-5
Myocardium [23] 70.3 - - 0.96 1 2.17 2.67 0.8 0.03
Whole heart [24] 52.3 - - 1.28 1 - - - 1.66 × 10-4
Whole heart [23] 63.3 - - 0.93 1 - - - 0.032
Whole heart [23] 70.3 - - 0.96 1 2.11 1.92 1.1 0.028
Table 2 Predicted RNTCP values for cardiac structures for the
MB patient using combinations of NTCPmodel parameters
(min: D50 = 40 Gy, n= 1, m=0.05; max: D50 = 80 Gy, n=0.2,
m=0.5), the myocardium (min: D50 = 40 Gy, γ=1.5, s= 0.5;
max: D50 = 80 Gy, γ=0.8, s= 1), and the whole heart (min:
D50 = 40 Gy, γ= 1.5, s=0.5; max: D50 = 80 Gy, γ= 0.8, s=1)
Structure RNTCP
Minimum Baseline Maximum
Pericardium 0 1.43 × 10-5 0.57
Myocardium 0 0.03 0.19
Whole heart 0 0.03 0.18
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reasons. Howell et al. [18] recently reported that the
TPS used in this work (for 6 MV) was accurate to the level
of 5% of the prescribed dose. In this study, the heart and
major cardiac substructures were entirely within the 5%
isodose line for both patients; consequently, it was feasible
to accurately assess the organ dose directly using the
TPS. The equivalent dose in each organ, HT, was calcu-
lated by multiplying the organ dose, DT, by a mean
radiation weighting factor, —wR . The
—wR values were
taken as 1.1 for proton primary fields-that is, dose
values were reported in Gy (RBE)-and 1.0 for photon
fields. The mean radiation weighting factor —wR values
for neutrons were obtained from Monte Carlo simulations
(unpublished data) and previous report [8], following the
methods in literature [8,19].
Based on modeling methods we found in a comprehen-
sive search of the literature, we calculated the relative risks
(RR) of radiogenic cardiac toxicity using the linear model
[20] (α1 = 0.6, 95% confidence interval [CI], 0.2 to 2.5) and
normal tissue complication probability (NTCP) using
relative seriality (RS) [21] and Lyman [22] models.
(The models are summarized in the Appendix.)
Table 1 lists the NTCP model parameter sets from the
literature. The model parameters are from patients treated
for HD [23], breast cancer [24], esophageal cancer [25],
and historical outcome data [26]. Only the parameters
based on HD data were used in the risk calculations for
the HD patient in this study. However, to our knowledge,
the literature contains no report that establishes a detailed
relationship between radiation dose and the incidence
of cardiac toxicity for MB patients. Consequently,
NTCP model parameters specific to MB patients were
not available. Thus, all the possible sets of parameters
in Table 1 were tried for the MB patient, but the ratios of
NTCP (RNTCP), from proton therapy to photon therapy,
were presented instead of NTCP values themselves,
because of the large uncertainties associated with the
NTCP values.To compare risk values between photon and proton
plans, we defined the ratio of RR (RRR), based on the
linear model, as
RRR ¼ RRproton=RRphoton; ð1Þ
and the RNTCP was defined as
RNTCP ¼ NTCPproton=NTCPproton: ð2Þ
The mean whole-heart doses were used to calculate
RR values. Dose volume histograms (DVHs) for heart
structures were exported from the TPS to calculate
the corresponding NTCP values. For the photon plan,
the DVHs were taken from the TPS directly. For the
proton plan, the DVHs for primary dose were obtained
from the TPS and a mean neutron equivalent dose
(neutron absorbed dose multiplied by neutron —wR ) was
then added uniformly to the primary DVH, which was
appropriate considering the secondary neutron dose was
spatially nearly uniform. Each step in the differential DVH
was corrected to a 2 Gy or Gy (RBE)/fraction schedule by
using the linear quadratic model [27]. An α/β ratio of 3
was chosen for the late effects in the heart [23].
Figure 1 Sensitivity tests. Sensitivity of the predicted (a) RRR values, and RNTCP values for the (b) pericardium, (c) myocardium, and (d) whole
heart to changes in the neutron radiation weighting factor —wR . The NTCP model parameters used for the calculations are listed in each panel.
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There are potentially large and poorly known uncertainties
in the NTCP model parameters for the MB patient. We
performed a sensitivity test of the predicted RNTCP values
to these uncertainties by varying each model parameter
over its plausible range (see Table 2).
There are large uncertainties associated with neutron —wR .
The International Commission on Radiological ProtectionPericar
Myocar
(a)
Figure 2 Heart substructure contouring: (a) baseline contouring, and (b[28] recommended in Publication 92 that the maximum
neutron wR should be 20. We performed a sensitivity test
to quantify the impact of uncertainty on the —wR values
by using different scaling factors in cardiac toxicity
calculations (see Figure 1).
Contouring of heart substructures was challenging
and may have introduced large uncertainties. In the
prevailing standard of care, CT imaging methods useddium
dium
(b)
) revised contouring that was used for uncertainty analysis.
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do not clearly show these substructures. The methods
for radiographic identification and delineation of the
heart substructures are not standardized, and knowledge
of the uncertainty in the contouring process is incom-
plete [24,25,29]. For these reasons, we performed
sensitivity tests to quantify the influence of heart
contouring on the RNTCP values. We redefined the
pericardium as a 1-cm shell (i.e., 5 times thicker than
the shell in the baseline calculations) inside the exter-




Figure 3 Axial and sagittal slices of dose distributions from the photo
for the MB patient. Heart contour (red) was displayed for both patients, andshell inside the inner surface of the thicker pericardium
(Figure 2).
Results
Figure 3 shows therapeutic dose distributions in the
heart area from photon and proton treatment plans,
clearly revealing that proton beams provided a much
lower exit dose to the heart for the MB patient, while
comparable doses were delivered to the heart from both
plans for the HD patient. The mean organ doses to










n and proton plans. (a, b) Slices for the HD patient and (c, d) slices
CTV contour (blue) was displayed for the HD patient.
Table 3 Mean organ doses (Gy) and equivalent doses (Sv) to heart and substructures from proton and photon plans










Primary Stray Primary Stray Total
Pericardium 0.55 0.032 0.61 0.26 0.87 10.59 10.59
MB Myocardium 0.13 0.033 0.14 0.26 0.40 11.72 11.72
Whole heart 0.19 0.032 0.21 0.26 0.47 12.31 12.31
Pericardium 11.15 0.081 12.27 0.69 12.96 14.26 14.26
HD Myocardium 9.05 0.077 9.95 0.65 10.60 12.23 12.23
Whole heart 8.90 0.078 9.79 0.66 10.45 12.28 12.28
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Figure 4 shows the differential DVHs from photon and
proton plans.
The RR values of cardiac toxicity following proton
and photon therapies for the HD patient were 7.27
(95% CI, 3.09 to 27.12) and 8.37 (95% CI, 3.46 to
31.70), respectively, and the corresponding RRR was
0.87. The RR values following proton and photon CSI
for the MB patient were 1.28 (95% CI, 1.09 to 2.18)
and 8.39 (95% CI, 3.46 to 31.78), respectively, and the
corresponding RRR was 0.15.
Table 1 lists the predicted NTCP and RNTCP values
for the heart structures. The NTCP values for the HD
patient were 2.17% (proton) and 2.67% (photon) with
the myocardium as the organ at risk, and were 2.11%
(proton) and 1.92% (photon) with the whole heart as the
organ at risk. The predicted RNTCP values for the MB
patient were always much less than unity, regardless of
the parameter sets used.
Figure 5 plots RNTCP values for the whole heart,
myocardium, and pericardium for the MB patient, using
various NTCP model parameters. The Lyman model was
tested for the pericardium, while the RS model was
tested for the myocardium and the whole heart. For the
pericardium, the RNTCP values were not sensitive to
changes in n values but were sensitive to changes in
D50 values and very sensitive to changes in m values
(as m increased from 0.1 to 1, the RNTCP increased
substantially). For the myocardium and the whole
heart, the RNTCP values were not sensitive to
changes in D50 or s values but were very sensitive to
changes in γ values (as γ increased from 0.1 to 2, the
RNTCP decreased substantially). Given these results,
we selected reasonable combinations to estimate the
minimum and maximum RNTCP values (Table 2). The
intervals for the NTCP model parameters were set large
enough to include all published parameters from the
literature. Results of the RNTCP calculations are listed in
Table 2, and they are all less than unity.
The sensitivity of RRR to scaling factor of neutron —wR
values and the sensitivity of RNTCP to the —wR scalingfactor are shown in Figure 1. The RRR value changed
between 0.85 and 1.29 for the HD patient as the —wR value
was scaled from 0.5 times to 10 times the nominal value;
they were less than unity for the MB patient in all cases
considered. The RNTCP values varied between 0.79 and
1.36 for the HD patient with myocardium as the organ
at risk, and they varied between 1.06 and 1.86 for the
HD patient with the whole heart as the organ at risk.
The RNTCP values were all much less than unity for the
MB patient.
The RNTCP calculations obtained when using different
heart-contouring methods are listed in Table 4. In all
cases, the predicted RNTCP values did not change much
from the baseline for both patients.
Discussion
We predicted risks of cardiac toxicities for a 4-year-old boy
receiving photon or proton CSI for MB and a 10-year-old
girl receiving photon or proton therapy for HD. Thera-
peutic and stray radiation doses were considered. To our
knowledge, this study incorporated, for the first time,
patient-specific stray neutron doses into the NTCP calcula-
tions. We used published model parameters in the risk
calculations, and we examined the sensitivity of RR values
to NTCP model parameter values, the neutron —wR values
and heart contouring. The major finding of this study is
that proton and photon therapies conferred comparable
predicted risk of radiogenic cardiac toxicity for the HD
patient, and proton therapy reduced the risk for the MB
patient compared to photon therapy.
Our predicted RR and NTCP values for the HD patient
agree well with those in the literature, in which the rela-
tive risks of cardiac mortality among HD patients range
from 2.2 to 12.7 [3], and the relative risk of myocardial
infarction of pediatric HD survivors is reported as 12.2
(95% CI, 5.2 to 28.2) [30]. Those data agree well with
our calculated RR of 8.37 (95% CI, 3.46 to 31.7) for the
photon plan, considering that most of the historical
treatments used photon techniques. The absolute excess
risk of cardiac mortality ranges from 0.093% to 0.5% per

























































Figure 4 Differential DVHs of the whole heart and heart substructures. DVHs from (a) proton and (b) photon treatment plans for the MB
patient and the HD patient. For the photon plan, the DVHs were taken from TPS directly; for the proton plan, the DVHs for primary dose were
obtained from TPS, then a mean neutron equivalent dose was added uniformly to the primary DVHs.
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exposure. Our predicted NTCP values at 5 years
after exposure were 2.67% for myocardium and
1.92% for the whole heart. Again, they are in reasonable
agreement with the literature.
The RRR and RNTCP values for cardiac toxicity
were sensitive to the uncertainties in —wR for neutrons.Especially for the HD patient, the RRR and RNTCP
values were higher than unity when —wR was scaled to
high values, indicating that the predicted risk of car-
diac toxicity from proton therapy may be higher than
that from photon therapy if the RBE of stray neutrons
is large. While the advantage of proton therapy is not















s = 0.1, 0.5, 1 s = 0.1, 0.5, 1
D50 (Gy) D50 (Gy)
D50 (Gy)
D50 (Gy)
D50 (Gy) D50 (Gy)
Figure 5 Surfaces of predicted RNTCP values for heart substructures as functions of different NTCP parameters for the MB patient.
(Top) The surfaces displayed were calculated for m values of 0.1, 0.3, 0.5, and 1 (pericardium) and γ values of 0.1, 0.5, 1, and 2 (myocardium and
whole heart). (Bottom) The surfaces displayed were calculated for n values of 0.1, 0.3, 0.5, and 1 (pericardium) and s values of 0.1, 0.5, and 1
(myocardium and whole heart). Color has been interpolated to facilitate visualization.
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decrease risks of other late effects [32,33]. It is possible that
risk from proton therapy could be reduced if IMPT were
used rather than PSPT. However, we focused on PSPT
because it is the technique that is most widely available.
Considering the breadth of NTCP model parameters
we tested, and the substantial differences in the dose
distributions between proton and photon CSI, we interpret
the results of this work as suggesting that proton CSI
carries a lower risk of cardiac toxicity than photon CSI. In
this type of predictive analysis, the calculated NTCP values
are highly dependent on the clinical data and thus are
more suitable for comparing the relative risks of treatments







(NTCPProton = 2.17%, NTCPPhoton = 2.67%) (NTCPThis study has some limitations. First, we used a single
case for each type of disease. While CSI is the standard
for MB treatment, various treatment fields exist for HD
patients. However, the emphasis of this paper is on the
methodology and this paper is the preliminary report of a
follow-up cohort study, which is being carried out by our
group. Second, we applied risk models that carry large
uncertainties to the MB patient. However, our sensitivity
test revealed the robustness of the qualitative finding that
proton CSI carries a lower risk of cardiac toxicity than
photon CSI. Third, the heart contouring was simplified in
this study, but we believe this kind of simplification is
warranted, given the large uncertainties associated with




- 1.43 × 10-5 1.49 × 10-5
1.27 0.03 0.024
Proton = 1.24%, NTCPPhoton = 0.98%)
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conclusion. Finally, we only considered radiation induced
cardiac toxicity because this is the focus of this study,
while chemotherapy was also reported to significantly
increase risk of cardiac toxicity [20,35]. However, according
to Tukenova et al. [20], the radiation dose did not signifi-
cantly interact with chemotherapy dose, which justified the
risk calculations in our study.
Conclusion
Proton therapy conferred a similar risk of radiogenic
cardiac toxicity as photon therapy for the HD patient in
this study, while substantially reducing the risk for the MB
patient in this study. Sensitivity analyses revealed that RRR
and RNTCP values were sensitive to uncertainty in the
mean neutron —wR values, and RNTCP was sensitive to the
NTCP model parameters but not sensitive to variations in
the heart structure contours. The qualitative findings
of the study were not sensitive to the uncertainties in
these factors.
Appendix
Tukenova et al. [20] reported a relationship between the
mean radiation dose to the heart and the risk of cardiac
mortality based on a large sample of follow-up data on
childhood cancer survivors and they concluded the best
dose–response model was:
RR ¼ 1þ α1D; ð3Þ
where RR is the relative risk, D is the mean heart dose, and
α1, which is the linear coefficient, is 0.6 (95% CI, 0.2 to 2.5).
The same group reported a linear model to estimate risk of
cardiac disorder and a linear quadratic model to estimate
risk of cardiac failure in 2006 [36]. Considering that refe-
rence [20] is the most up-to-date, the linear model in it was
chosen for this study.
The relative seriality model is based on the Poisson
model of cell survival [21]. The probability of cell death
when irradiating a tissue to dose D is
P Dð Þ ¼ 2− exp eγ 1−D=D50ð Þf g; ð4Þ
where γ is the maximum relative slope of the dose–
response curve and D50 is the dose that will result in
a 50% probability of a complication. The normal tissue
complication probability (NTCP) due to inhomogeneous




1−P Dið Þs½ V i=V
( )1=s
; ð5Þ
where s is the relative seriality that describes the hybrid
serial/parallel architecture of the organ, (s = 0 indicates pa-
rallel organization, while s = 1 indicates serial organization),n is the number of voxels in the dose-calculation volume,
Di is the dose in each subvolume,Vi is the volume of each
subvolume in the differential dose-volume histogram, and
V is the total volume of the organ.
The Lyman model [22] assumes that the probability of
complication is a normal distribution as a function of








t ¼ D−TD50 Vð Þð Þ= m⋅TD50 Vð Þð Þ ð7Þ
TD50 Vð Þ ¼ TD50 1ð Þ=Vn ð8Þ
where TD50(V) is the tolerance dose that would result in
a 50% complication probability for the partial volume V,
TD50(1) is the tolerance dose that would result in a 50%
complication probability for the full organ, n indicates
the volume effect (n close to 1 means the volume effect
is strong), and m is inversely proportional to the slope of
the dose–response curve.
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